ProfileGDS5678 / 1434879_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 89% 87% 85% 88% 88% 89% 88% 87% 86% 85% 86% 87% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6740387
GSM967853U87-EV human glioblastoma xenograft - Control 27.0586289
GSM967854U87-EV human glioblastoma xenograft - Control 36.6823887
GSM967855U87-EV human glioblastoma xenograft - Control 46.5646485
GSM967856U87-EV human glioblastoma xenograft - Control 56.8890388
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5657588
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.858189
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.826688
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5974487
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6097786
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.2993585
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.512986
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.753187
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.6166287